Evidence map›Paper›PMID 33036618›Full record

ArticleJournal of translational medicine2020

Closing the system: production of viral antigen-presenting dendritic cells eliciting specific CD8

Jean-Philippe Bastien, Natalie Fekete, Ariane V Beland, Marie-Paule Lachambre, Veronique Laforte, David Juncker, Vibhuti Dave, Denis-Claude Roy, Corinne A Hoesli

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jean-Philippe BastienHematology-Oncology and Cell Therapy Institute, Hopital Maisonneuve-Rosemont Research Center, Montreal, Québec, Canada.
Natalie FeketeDepartment of Chemical Engineering, McGill University, Montreal, Québec, Canada.
Ariane V BelandDepartment of Chemical Engineering, McGill University, Montreal, Québec, Canada.
Marie-Paule LachambreHematology-Oncology and Cell Therapy Institute, Hopital Maisonneuve-Rosemont Research Center, Montreal, Québec, Canada.
Veronique LaforteDepartment of Biomedical Engineering, McGill University, Montreal, Québec, Canada.
David JunckerDepartment of Biomedical Engineering, McGill University, Montreal, Québec, Canada.
Vibhuti DaveHematology-Oncology and Cell Therapy Institute, Hopital Maisonneuve-Rosemont Research Center, Montreal, Québec, Canada.
Denis-Claude RoyHematology-Oncology and Cell Therapy Institute, Hopital Maisonneuve-Rosemont Research Center, Montreal, Québec, Canada.
Corinne A HoesliDepartment of Chemical Engineering, McGill University, Montreal, Québec, Canada. corinne.hoesli@mcgill.ca.ORCID 0000-0002-5629-7128
Hôpital Maisonneuve-Rosemont · CAMcGill University · CAMcGill Genome Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA major obstacle to anti-viral and -tumor cell vaccination and T cell immunotherapy is the ability to produce dendritic cells (DCs) in a suitable clinical setting. It is imperative to develop closed cell culture systems to accelerate the translation of promising DC-based cell therapy products to the clinic. The objective of this study was to investigate whether viral antigen-loaded monocyte-derived DCs (Mo-DCs) capable of eliciting specific T cell activation can be manufactured in fluorinated ethylene propylene (FEP) bags.

methodsMo-DCs were generated through a protocol applying cytokine cocktails combined with lipopolysaccharide or with a CMV viral peptide antigen in conventional tissue culture polystyrene (TCPS) or FEP culture vessels. Research-scale (< 10 mL) FEP bags were implemented to increase R&D throughput. DC surface marker profiles, cytokine production, and ability to activate antigen-specific cytotoxic T cells were characterized.

resultsMonocyte differentiation into Mo-DCs led to the loss of CD14 expression with concomitant upregulation of CD80, CD83 and CD86. Significantly increased levels of IL-10 and IL-12 were observed after maturation on day 9. Antigen-pulsed Mo-DCs activated antigen-responsive CD8

conclusionsOur findings demonstrate that viral antigen-loaded Mo-DCs produced in downscaled FEP bags can elicit specific T cell responses. In view of the dire clinical need for closed system DC manufacturing, FEP bags represent an attractive option to accelerate the translation of promising emerging DC-based immunotherapies.

Indexed as

Antigens, ViralDendritic CellsCell Culture TechniquesFluorocarbon PolymersMonocytesPolytetrafluoroethyleneAntigens, Viralfluorinated ethylene propyleneFluorocarbon PolymersPolytetrafluoroethyleneCellular therapyDendritic cellFluorinated polymersImmunotherapyMonocytePolystyreneScale-down

Identifiers

PMID33036618
PMCPMC7547414
OpenAlexW3092326857

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.